Novel outcome measures for clinical trials in cystic fibrosis

Harm A.W.M. Tiddens, Michael Puderbach, Jose G. Venegas, Felix Ratjen, Scott H. Donaldson, Stephanie D. Davis, Steven M. Rowe, Scott D. Sagel, Mark Higgins, David A. Waltz

Research output: Contribution to journalArticle

24 Scopus citations


Cystic fibrosis (CF) is a common inherited condition caused by mutations in the gene encoding the CF transmembrane regulator protein. With increased understanding of the molecular mechanisms underlying CF and the development of new therapies there comes the need to develop new outcome measures to assess the disease, its progression and response to treatment. As there are limitations to the current endpoints accepted for regulatory purposes, a workshop to discuss novel endpoints for clinical trials in CF was held in Anaheim, California in November 2011. The pros and cons of novel outcome measures with potential utility for evaluation of novel treatments in CF were critically evaluated. The highlights of the 2011 workshop and subsequent advances in technologies and techniques that could be used to inform the development of clinical trial endpoints are summarized in this review.

Original languageEnglish (US)
Pages (from-to)302-315
Number of pages14
JournalPediatric pulmonology
Issue number3
StatePublished - Mar 1 2015


  • CFTR activity
  • Cystic fibrosis
  • Endpoints
  • Imaging
  • Outcome measures
  • Sputum biomarkers

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Novel outcome measures for clinical trials in cystic fibrosis'. Together they form a unique fingerprint.

  • Cite this

    Tiddens, H. A. W. M., Puderbach, M., Venegas, J. G., Ratjen, F., Donaldson, S. H., Davis, S. D., Rowe, S. M., Sagel, S. D., Higgins, M., & Waltz, D. A. (2015). Novel outcome measures for clinical trials in cystic fibrosis. Pediatric pulmonology, 50(3), 302-315.